Pharmaceuticals

Revenue of the Neurogenic Detrusor Overactivity Market Predicted to Achieve $2.63 Billion by 2030, Driven by 7.6% CAGR

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neurogenic detrusor overactivity market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Neurogenic Detrusor Overactivity Market in 2026, and what figure is it projected to hit by 2030?

The neurogenic detrusor overactivity market has experienced robust growth in recent years. This market is forecast to expand from $1.82 billion in 2025 to $1.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. The historical growth can be attributed to several factors including limited treatment options for NDO, a reliance on conventional surgical interventions, the growing prevalence of neurogenic bladder disorders, increasing hospital and urology clinic infrastructure, and a lack of patient and caregiver education.

The neurogenic detrusor overactivity market is projected for substantial expansion in the coming years, reaching $2.63 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. This projected increase is linked to several factors, including the emergence of new pharmacological treatments, progress in minimally invasive surgical techniques, the incorporation of neuromodulation devices, wider use of continuous patient monitoring solutions, and increased funding for long-term care and rehabilitation. Key trends anticipated during this period encompass the growing acceptance of antimuscarinic and beta-3 adrenergic agonists, an uptick in the application of neuromodulation and minimally invasive treatments, the broadening of behavioral therapy and patient education initiatives, a heightened emphasis on urodynamic and ultrasound surveillance, and a greater understanding of quality of life evaluations and sustained care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24619&type=smp

Which Drivers Are Affecting Market Participation In The Neurogenic Detrusor Overactivity Market?

The increasing occurrence of neurological disorders is anticipated to stimulate the future expansion of the neurogenic detrusor overactivity market. Neurological disorders are defined as medical conditions impacting the brain, spinal cord, or nerves, resulting in challenges with movement, sensation, cognitive function, or other bodily processes. The rise in these disorders is linked to longer human lifespans, which increases the likelihood of age-related brain degeneration. Neurogenic detrusor overactivity (NDO) is a bladder dysfunction frequently associated with neurological conditions such as spinal cord injury, multiple sclerosis, and Parkinson’s disease. These conditions disrupt the normal nerve communication between the brain and bladder, leading to involuntary contractions of the bladder. For instance, in April 2024, a study published by the American Academy of Neurology (AAN), a US-based neurology and neuroscience organization, projected an estimated 4.9 billion cases of brain disorders globally by 2050, representing a 22% increase from approximately 4 billion cases in 2021. Therefore, the growing incidence of neurological disorders is a key driver for the neurogenic detrusor overactivity market’s growth.

What Segment Categories Are Covered In The Neurogenic Detrusor Overactivity Market?

The neurogenic detrusor overactivity market covered in this report is segmented –

1) By Types: Non-Surgical Treatment, Surgical Treatment, Follow-Up Treatment

2) By Application: Adult, Child

3) By End-User: Hospitals, Urology Clinics, Rehabilitation Centers, Private Practices, Long-Term Care Facilities

Subsegments:

1) By Non-Surgical Treatment: Antimuscarinic Drugs, Beta-3 Adrenergic Agonists, Behavioral Therapy, Neuromodulation, Clean Intermittent Catheterization, Intravesical Therapies

2) By Surgical Treatment: Botulinum Toxin Injection, Augmentation Cystoplasty, Urinary Diversion, External Sphincterotomy, Artificial Urinary Sphincter Implantation

3) By Follow-Up Treatment: Urodynamic Evaluation, Ultrasound Monitoring, Laboratory Tests, Ongoing Catheterization, Repeat Botulinum Toxin Injections, Patient and Caregiver Training, Quality of Life Assessment

How Are New Market Trends Shaping The Landscape Of The Neurogenic Detrusor Overactivity Market?

Leading companies within the neurogenic detrusor overactivity (NDO) treatment market are concentrating on developing sophisticated generic therapeutics, such as beta-3 adrenergic receptor agonists, to provide efficient bladder control solutions at lower expenses. These beta-3 adrenergic receptor agonists, exemplified by mirabegron, work by relaxing the detrusor muscle in the bladder, which in turn enhances bladder capacity and lessens symptoms like urgency and incontinence. For example, in April 2024, Lupin Ltd., an India-based pharmaceutical firm, secured approval from the U.S. Food and Drug Administration (USFDA) to introduce Mirabegron, the generic variant of Myrbetriq, in the United States. As an advanced once-daily oral therapy, Mirabegron provides a practical and effective treatment choice for pediatric patients suffering from overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). This endorsement highlights Lupin’s dedication to increasing the availability of superior, cost-effective generic medications in key therapeutic domains.

Which Leading Companies Dominate The Neurogenic Detrusor Overactivity Market Share?

Major companies operating in the neurogenic detrusor overactivity market are Astellas Pharma Inc., Medtronic plc, Ipsen, Coloplast A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Apotex Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Aurobindo Pharma Limited, Hugel Inc., Abbott Laboratories, Boston Scientific Corporation, Cook Medical, Convatec Group plc, B. Braun Melsungen AG, Teleflex Incorporated, Olympus Corporation, Karl Storz SE & Co. KG, Laborie Medical Technologies, Wellspect HealthCare (DENTSPLY Sirona), Hollister Incorporated, Uroplasty Inc., Endo Pharmaceuticals Inc., Ferring Pharmaceuticals, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Zydus Lifesciences Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neurogenic-detrusor-overactivity-global-market-report

How Does The Neurogenic Detrusor Overactivity Market Perform Across Major Global Regions?

North America was the largest region in the neurogenic detrusor overactivity market in 2025. The regions covered in the neurogenic detrusor overactivity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neurogenic Detrusor Overactivity Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24619&type=smp

Browse Through More Reports Similar to the Global Neurogenic Detrusor Overactivity Market 2026, By The Business Research Company

Peripheral Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Neurotoxin Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurotoxin-global-market-report

Diabetic Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795